Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

influenza vaccine

- PMLiVE

UK to provide genomic sequencing globally to identify COVID-19 variants

Public Health England has identified the first group of countries to receive genomic sequencing support through NVAP

- PMLiVE

Bharat Biotech says its COVID-19 vaccine is 77.8% effective overall

US development partner Ocugen is already planning to submit a BLA for the vaccine to the FDA

- PMLiVE

J&J’s COVID-19 vaccine shows ‘strong’ activity against Delta variant

Vaccine produces durable immune responses lasting up to eight months

- PMLiVE

COVID-19 booster dose programme planned for September launch in Britain

The programme will be conducted in two stages for a range of priority groups

- PMLiVE

Cambridge University scientists identify 160 new drugs with COVID-19 repurposing potential

Scientists highlighted the potential of two drugs, one for rheumatoid arthritis and one for malaria

- PMLiVE

Final data shows CureVac’s COVID-19 vaccine is only 48% effective

New data shows slight improvement over previously reported 47% overall efficacy in interim analysis

- PMLiVE

Moderna says its COVID-19 vaccine appears effective against Delta and other variants

Earlier this year, the company revealed early evidence that its booster jabs may be effective against ‘variants of concern’

- PMLiVE

Pardes Biosciences, backed by Gilead and Foresite, goes public to advance lead COVID-19 antiviral drug

Pardes’ lead oral antiviral drug candidate is designed to inhibit the main protease of SARS-CoV-2

- PMLiVE

Study finds mixed vaccine schedules provide strong immune response against COVID-19

And AZ's Vaxzevria COVID-19 vaccine shows strong immune responses following a delayed second dose

- PMLiVE

US pauses shipments of Eli Lilly’s COVID-19 antibody treatment due to variant concerns

Laboratory analyses found the therapy was not effective against variants first discovered in South Africa and Brazil

- PMLiVE

Oxford University to study antiparasitic drug ivermectin in COVID-19 trial

The potential COVID-19 treatment will be investigated as part of the large-scale PRINCIPLE trial

- PMLiVE

Tonix Pharmaceuticals to develop TNX-102 for long COVID syndrome

TNX-102 is already in phase 3 development for the treatment of fibromyalgia

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links